Johnson & Johnson reported strong Q2 2013 results, exceeding expectations and raising full-year guidance despite currency headwinds. The pharmaceutical segment showed robust growth driven by new products, and the restoration of the U.S. OTC business is progressing well. Management's positive tone and improved outlook suggest a positive short-term impact on the stock price.

[1]